Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?

Hum Immunol. 2018 Jul;79(7):532-536. doi: 10.1016/j.humimm.2018.04.008. Epub 2018 Apr 13.

Abstract

Background: Matching at the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci is important in donor selection for patients undergoing unrelated allogeneic hematopoietic stem cell transplantation (ASCT). Additional matching across the MHC gamma region may further improve outcomes.

Methods: The MHC gamma region was retrospectively genotyped in 66 adult recipients of ASCT and their 10/10 matched unrelated donors. A chart review was performed to determine whether MHC gamma matching impacted survival, relapse, or graft-versus-host disease.

Results: Of 66 donor-recipient pairs, 26(39.4%) were gamma-type matches, 34(51.5%) were mismatches, and 6(9.1%) were "indeterminate." Matching status was not associated with overall survival (p = 0.43), relapse (p = 0.21), acute GVHD (p = 0.43), severe aGVHD (p = 0.31), or chronic GVHD (p = 0.23) in univariate analyses, nor in multivariate analyses (p = 0.28, 0.13, 0.29, 0.16, and 0.67, respectively), with or without adjusting for HLA-DPB1 matching status.

Conclusions: In our single institution study, gamma-type matching status was not associated with outcomes of adult ASCT recipients.

Keywords: Allogeneic stem cell transplantation; MHC Class III; MHC gamma.

MeSH terms

  • Adult
  • Aged
  • Complement System Proteins / genetics
  • Female
  • Genotype*
  • HLA Antigens / genetics*
  • Heat-Shock Proteins / genetics
  • Hematologic Neoplasms / immunology*
  • Hematologic Neoplasms / mortality
  • Histocompatibility
  • Histocompatibility Testing
  • Humans
  • Major Histocompatibility Complex / genetics*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Retrospective Studies
  • Stem Cell Transplantation*
  • Survival Analysis
  • Tissue Donors
  • Transplant Recipients
  • Transplantation, Homologous
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • HLA Antigens
  • Heat-Shock Proteins
  • Tumor Necrosis Factor-alpha
  • Complement System Proteins